• IGF2BP3–FZD1/7 Axis Drives Stemness and Carboplatin Resistan

  2026-05-28

  This study identifies IGF2BP3 as a pivotal m6A reader that stabilizes FZD1/7 transcripts, thereby driving cancer stem-like cell maintenance and carboplatin resistance in triple-negative breast cancer (TNBC). These findings reveal a new therapeutic vulnerability in TNBC, highlighting the IGF2BP3–FZD1/7–β-catenin pathway as a promising target to overcome chemoresistance.

• DMH-1 and the Art of Precision BMP Inhibition in Translation

  2026-05-28

  Explore how DMH-1, a highly selective ALK2 inhibitor, is redefining experimental control in both organoid engineering and non-small cell lung cancer (NSCLC) research. This thought-leadership article integrates mechanistic insights, recent peer-reviewed advances, and strategic guidance for translational researchers seeking reliable modulation of BMP signaling. Building on current literature, we examine DMH-1’s unique value proposition, offer actionable protocol parameters, and provide a forward-looking perspective on the future of precision pathway inhibition.

• Hydrocortisone (SKU B1951): Technical Guidance for Research

  2026-05-27

  Hydrocortisone provides researchers with a reliable glucocorticoid hormone for standardized modulation of metabolic, immune, and inflammatory pathways in cell and animal models. It is best suited for applications requiring reference-grade compound quality and defined solubility, but is not appropriate for experiments requiring aqueous stocks or long-term solution storage.

• CCG-1423: RhoA Inhibitor Optimizes Cancer and Viral Assays

  2026-05-27

  CCG-1423, a potent RhoA inhibitor from APExBIO, empowers researchers to dissect RhoA/ROCK signaling in both cancer and virology models. This article details practical workflows, parameter guidance, and troubleshooting tips to maximize experimental success in advanced apoptosis and tight junction assays.

• Cyclosporin A: Optimizing Immunosuppression and Assay Design

  2026-05-26

  Cyclosporin A is the benchmark immunosuppressant for dissecting T-cell signaling, mitochondrial function, and translational immunology. Here, we break down actionable protocols, troubleshooting, and recent advances that empower researchers to harness its specificity, as validated by cyclophilin A-deficient models.

• Optimizing Fibrosis Models with SB525334 TGF-beta1 Receptor

  2026-05-26

  SB525334, a potent TGF-beta1 receptor inhibitor from APExBIO, enables precise dissection of TGF-β1/Smad2/3 signaling in fibrosis and wound healing models. This article translates cutting-edge findings on bone transport-mediated tissue repair into actionable workflows and troubleshooting strategies for researchers targeting the TGF-β pathway.

• Berberine Suppresses SASP Inflammation via RXRα/PPARγ/NEDD4

  2026-05-25

  This study elucidates how berberine inhibits senescence-associated secretory phenotype (SASP)–mediated inflammation in atherosclerosis by activating the RXRα/PPARγ/NEDD4 pathway. The findings reveal a mechanistic framework for targeting chronic vascular inflammation and inform experimental approaches to dissect PPARγ signaling in aging and cardiovascular disease.

• A 83-01 (ALK-5 Inhibitor): Optimizing TGF-β Pathway Control

  2026-05-25

  A 83-01 (ALK inhibitor) delivers precise, tunable suppression of TGF-β/Smad signaling, empowering advanced organoid models to balance self-renewal and differentiation. This guide translates recent breakthroughs and hands-on protocol enhancements for researchers seeking reliable, high-purity pathway modulation with APExBIO’s trusted reagent.

• Baicalin in Translational Research: Pathway Precision & Plas

  2026-05-24

  This article explores Baicalin's mechanistic influence on neuroplasticity and cancer pathways, offering translational researchers actionable guidance for protocol design and experimental differentiation. By integrating recent evidence from adult amblyopia models and advanced pathway modulation, we position APExBIO's Baicalin as a transformative reagent for studies at the frontier of neurobiology and oncology.

• MK-4827 (Niraparib): Reliable PARP-1/-2 Inhibition in Cancer

  2026-05-23

  This article addresses key experimental challenges in DNA damage repair inhibition, focusing on how 'MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor' (SKU A3617) from APExBIO delivers reproducible, sensitive, and workflow-compatible solutions for cancer research. Drawing on literature and real-world scenarios, we explore protocol parameters, data interpretation, and vendor selection to help researchers optimize BRCA-mutant and DNA repair-deficient cell assays.

• Honokiol Triggers Paraptosis in APL via mTOR and MAPK Pathwa

  2026-05-22

  This study uncovers that honokiol induces paraptosis-like cell death, independent of apoptosis, in acute promyelocytic leukemia (APL) cells via activation of mTOR and MAPK signaling. These findings highlight a novel mechanism for targeting apoptosis-resistant leukemia, suggesting potential new research directions for non-apoptotic cancer therapies.

• PP2A-Mediated Autophagy Drives Drug Resistance in C. albican

  2026-05-22

  This study reveals that protein phosphatase 2A (PP2A) induces autophagy via ATG protein phosphorylation, facilitating biofilm formation and antifungal drug resistance in Candida albicans. The findings suggest autophagy modulation as a promising approach for improving antifungal therapy against biofilm-associated infections.

• NF 340: Selective P2Y11 Antagonist for Advanced Signaling St

  2026-05-21

  NF 340 stands out as a potent, selective P2Y11 antagonist, enabling precise dissection of purinergic and GPCR signaling in cancer and immunology research. This article details hands-on workflow enhancements, troubleshooting strategies, and experimental insights—anchored by recent mechanistic discoveries in breast cancer invasiveness.

• Synergistic Suppression of EMT in PDAC via CDK4/6 and BET In

  2026-05-21

  Gu et al. (2025) demonstrate that combined CDK4/6 and BET inhibition synergistically suppresses pancreatic ductal adenocarcinoma progression by modulating the GSK3β-mediated Wnt/β-catenin pathway and reversing EMT. This integrated strategy addresses the paradoxical pro-metastatic effects of CDK4/6 monotherapy and informs future targeted therapy designs for PDAC.

• Calpeptin as a Calpain Inhibitor: Protocols for Fibrosis Res

  2026-05-20

  Calpeptin stands out as a potent calpain inhibitor with validated efficacy in modulating fibrosis and inflammation, enabling precise mechanistic studies and reproducible workflows. This guide details best-practice experimental setups, advanced applications, and troubleshooting strategies for maximizing Calpeptin’s performance in fibrosis and cell death research.

16146 records 1/1077 page Next 12345 下5页 Last page